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Abstract
Background: Periprocedural antithrombotic prophylaxis in patients undergoing surgical valve 
procedures (SVP) is insufficiently investigated. Low molecular weight heparin (LMWH) has been 
considered as an alternative to unfractionated heparin (UFH). However, safety and efficacy of this 
prophylaxis strategy is unknown. This study aimed to investigate safety and efficacy of periprocedural 
LMWH prophylaxis and determine optimal dosage and timing for periprocedural cessation and 
initiation. 
Methods: The present study is a retrospective, single-center observational analysis of 388 patients who 
underwent SVP (valve replacement or valvuloplasty) between 2015 and 2016. In-hospital endpoints 
were bleeding, transfusions, reoperation due to bleeding, and thromboembolic events. 
Results: Giving the first dose of LMWH on the day of SVP was a risk factor for bleeding (OR 1.07; 95% 
CI 1.04–1.10; p < 0.001), transfusions (OR 1.04; 95% CI 1.01–1.07; p = 0.008) and reoperation due 
to bleeding (OR 1.20; 95% CI 1.12–1.28; p < 0.001), with > 40 mg/day as a predictor. A higher dosage 
of LMWH premedication was an independent risk factor for bleeding (OR 1.02; 95% CI 1.00–1.04; 
p = 0.03) and transfusion (OR 1.03; 95% CI 1.01–1.05; p = 0.01), with > 60 mg/day as a predictor 
for these events. LMWH dosed within 24 h prior to SVP increased the risk of transfusion (AUC 0.636; 
95% CI 0.496–0.762; p = 0.04). 
Conclusions: Bleeding is an important early concern after surgical valve procedures. Safety and effi-
cacy of periprocedural prophylaxis with LMWH depends on dosage and the timing of its administration. 
The most optimal periprocedural prophylaxis in the SVP population appears to be LMWH in dosage 
of 40–60 mg/day, which is recommended for deep vein thrombosis prophylaxis, ceased at least one day 
before SVP. (Cardiol J XXXX; XX, X: xx–xx)
Key words: surgical valve procedure, bleeding complications, antithrombotic  
prophylaxis
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Introduction
Thromboembolic and bleeding events account 
for nearly three-quarters of early complications af-
ter surgical valve replacement (SVR) [1]. The risk 
of thromboembolic events is the highest in the first 
days after the procedure, reaching 4–8 cases per 
100 patient-years [1–8]. However, the most com-
mon and life-threatening complication within the 
first 72 h after SVR is bleeding [1, 2, 9–12], which 
results from procedure-related coagulopathy caused 
by excessive consumption of plasma coagulation 
factors, enhanced platelet and fibrinolytic pathways 
activation during cardiopulmonary bypass (CPB), 
as well as a prolongation of coagulation cascade 
related to hypothermia [1, 13]. The risk of bleeding 
is further increased by the need for anticoagulation 
with unfractionated heparin (UFH) during SVR, 
reversal of its action with protamine sulfate, and 
its recirculation within 24 h after SVR [14, 15]. 
Although the early postprocedural period is bur-
dened with a high risk of bleeding, antithrombotic 
prophylaxis is nevertheless required at the onset 
of SVR to avoid prosthesis thrombosis. There is a 
paucity of evidence guiding optimal antithrombotic 
prophylaxis after SVR and current recommenda-
tions are inconsistent in this regard [8, 15–19]. The 
European Society of Cardiology (ESC) recommends 
UFH as the first line prophylaxis early after SVR, 
while subcutaneous low molecular weight heparin 
(LMWH) is considered as off-label [16]. There is 
a growing body of evidence from observational 
studies that suggests that prophylaxis with LMWH 
after SVR is as safe and as effective as UFH while 
also having an advantage of easier administration 
[1, 9–11]. The optimal dosage and timing of LMWH 
initiation after SVR remains unknown. There are 
scant evidence-based recommendations available 
for periprocedural antithrombotic prophylaxis in 
surgical valvuloplasty [16]. Adequate periproce-
dural antithrombotic prophylaxis in patients under-
going SVR is an unmet clinical need that requires 
further investigation.
Therefore, this study aims to evaluate the 
safety and efficacy of periprocedural LMWH and 
to determine optimal dosage and timing of LMWH 
cessation before and initiation after surgical valve 
procedures (SVP). 
Methods
This was a single-center, retrospective obser-
vational analysis. All consecutive patients who un-
derwent elective SVP including SVR, valvuloplasty, 
combined valve procedure with coronary artery 
bypass grafting (SVP+CABG), or with concomi-
tant ascending aorta replacement between January 
2015 and January 2016 were included. Patients who 
required aortic valve replacement due to aortic 
dissection, periprocedural intra-aortic balloon 
counter pulsation or hemodialysis due to severe 
perioperative renal insufficiency were excluded. 
Prosthesis selection (biological vs. mechanical) 
was based on currently recommended consensus 
guidelines, including previous indications for 
chronic anticoagulation [16]. Surgical procedures 
were performed with UFH to maintain an activated 
clotting time (ACT) above 400 s during CPB. After 
the procedure, protamine sulfate was given for 
reversal of UFH in a 0.8–1:1 ratio. In the event of 
an ACT > 130 s during postoperative recovery, 
additional doses of protamine or tranexamic acid 
were administered at the surgeon’s discretion. 
Two or three surgical drains (36 French) were 
placed around the heart and in the pleural cavi-
ties. Unless the drainage was not increased, drains 
were removed 1 day after SVP. Patients stayed 
in the intensive care unit or step-down unit until 
the second postoperative day. The two epicardial 
electrodes placed during SVR were removed on 
the third postoperative day.
The present institutional protocol herein, for 
periprocedural antithrombotic prophylaxis, con-
sisting of LMWH therapy without anti-Xa factor 
monitoring, was utilized for all patients included 
in the present analysis. The timing of cessation, 
timing of initiation, and dosage of LMWH before 
and after SVP were based on current guidelines and 
individualized based on the surgeon’s discretion, 
type of procedure, degree of achieved hemostasis, 
patient clinical condition, thromboembolic risk, 
body weight, and renal function [8, 15–19]. In the 
current protocol, LMWH was started 8–12 h after 
SVP with prophylactic dosages of 40–60 mg on the 
day of SVP and 40–80 mg on the first postoperative 
day, and then therapeutic dosages at 12-h intervals 
from the second postoperative day onwards. Oral 
anticoagulation (OAC) prophylaxis was started be-
tween the second and third postoperative days, after 
drains were removed as per patient clinical condition. 
LMWH was administered until the patient’s interna-
tional normalized ratio (INR) was within a therapeutic 
range (2–3 after aortic valve replacement, 2.5–3.5 
after mitral or tricuspid valve replacement).
Early antiplatelet prophylaxis with acetyl-
salicylic acid (ASA; 150 mg/day) was prescribed in 
cases of aortic bioprosthesis implantation, starting 
on SVP day, always in combination with LMWH 
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during the early post-procedural period. In cases of 
concomitant atrial fibrillation. LMWH/OAC mono-
therapy was recommended. Combined prophylaxis 
of LMWH/OAC with antiplatelet therapy (ASA/
clopidogrel) was prescribed in cases of mechani-
cal prosthesis implantation with CABG, recently 
performed percutaneous coronary intervention 
(PCI), or known peripheral arterial disease. In 
cases of bleeding early after SVP, antithrombotic 
prophylaxis with LMWH or antiplatelet agents 
was started after the achievement of proper he-
mostasis, in accordance with the aforementioned 
standardized criteria.  
The outcomes evaluated in this investigation 
were in-hospital bleeding, transfusions (packed red 
blood cells, platelet concentrate, or fresh frozen 
plasma), reoperation due to bleeding, and throm-
boembolic events. The risk factors evaluated in 
this investigation were periprocedural prophylaxis 
with LMWH and OAC, differing dosage of LMWH 
(mg/day) used before and after SVP, and timing of 
LMWH/OAC cessation and initiation before and 
after SVP (day). Additionally, the impact of pro-
cedure related parameters were assessed, such 
as dosage of UFH (IU) administered during the 
procedure, dosage of protamine at the end of SVP 
(mg), two subsequent ACT measurements after 
UFH and protamine administration, time on CPB 
(min), aorta clamping time (min), and arterial blood 
gas analyses before and after CPB. Preoperative 
and postoperative data were collected from patient 
medical history. Detailed information regarding 
procedures were obtained from reviews of patient 
medical records.  
All outcomes were assessed as in-hospital 
events and defined according to guidelines for re-
porting mortality and morbidity after cardiac valve 
intervention with the exception of bleeding [20]. 
Bleeding was defined according to the universal 
definition of perioperative bleeding in adult cardiac 
surgery, including moderate, severe and massive 
events (class 2–4) [21]. Although transfusion and 
reoperation due to bleeding are components of the 
bleeding definition, we also adopted these variables 
as separate endpoints. Thromboembolic events 
included prosthetic valve thrombosis, pulmonary 
embolism, peripheral thromboembolic events, 
stroke or transient ischemic attack.
Statistical analysis
Categorical data are presented as numbers 
and percentages. Continuous data are presented 
as mean ± standard deviation. Comparisons were 
made using the χ2 or two-sided Fisher exact test 
for categorical variables. Continuous data were 
compared using the Student t-test and Wilcoxon 
test, depending on their distribution as assessed 
by the Shapiro-Wilk test. The association between 
risk factors and outcomes were performed using 
univariate and multivariable logistic regression 
analysis to estimate an odds ratio (OR) and its 95% 
confidence interval (CI). Additionally, the impact 
of LMWH and OAC dosage and timing of initiation 
and cessation on endpoints was assessed through 
a receiver operating characteristic (ROC) curve 
and by estimating its area under the curve (AUC) 
and 95% CI. The optimal values for LMWH and 
OAC cut-off were chosen by taking into account 
the greatest sum of sensitivity and specificity. The 
predictive values of dosage and timing of LMWH/
OAC cessation and initiation were adjusted for 
potential confounding variables (Suppl. Table 1). 
Laboratory parameters were assessed on the day 
of SVP pre-procedure. A p-value < 0.05 was con-
sidered significant. All tests were performed using 
MEDcalc (Medcalc Software 2014). This study was 
approved by the Local Ethics Committee.
Results
This study included 388 consecutive SVP 
patients with a mean age of 63.6 ± 12.6 years. 
Among the 271 (69.84%) patients who underwent 
SVR, 161 (62.11%) patients received a mechanical 
prosthesis. Mechanical prostheses were implanted 
in mitral and aortic position in 42 (10.82%) and 
119 (30.67%) patients, respectively. The baseline 
characteristics of the study population and type of 
procedures performed are presented in Table 1.
Early bleeding occurred in 153 (39.33%) pa-
tients, being severe and massive only in 37 (9.45%) 
and 14 (3.61%) cases, respectively. Reoperation 
due to bleeding was required in 25 (6.45%) patients 
and was 2.5 ± 5.03 days after SVP. Transfusions 
were required in 203 (52.32%) patients. The first 
transfusion event was mainly performed during 
or early after SVP (0.59 ± 0.97 days). Thrombo-
embolic events were diagnosed in only 7 (1.8%) 
patients — all of them were early post-procedural 
strokes or transient ischemic attacks. Four (1.03%) 
deaths occurred during hospitalization. Two of the 
deceased had bleeding early after SVP, although 
bleeding was not the cause of death for any of them. 
Hospitalization time ranged between 4 and 30 days 
(mean 7.64 ± 2.92 days), and was significantly longer 
in those who bled (OR 1.19; 95% CI 1.09–1.29; p = 
0.001). All procedural and in-hospital outcomes 
are presented in Supplementary Table 1. The 
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impact of patient characteristics, type of procedure, 
and basic laboratory parameters on endpoints are 
presented in Supplementary Table 2. Peripro-
cedural antithrombotic prophylaxis in the study 
population and its impact on outcomes is presented 
in Figure 1.
Acetylsalicylic acid was the most commonly 
used antiplatelet agent pre-procedure (44.6% 
of patients), and after SVP (56.7% of patients). 
Clopidogrel premedication was used in 36 (9.3%) 
patients and significantly increased the risk of re-
operation due to bleeding (p = 0.04). No significant 
association between LMWH and OAC before SVP 
was found with any endpoint. Similarly, early post-
procedural LMWH prophylaxis had no impact on 
endpoints. Post-procedural OAC prophylaxis was 
significantly associated with reduced risk of bleed-
ing (p = 0.002), transfusion (p = 0.004), and reop-
eration due to bleeding (p = 0.029), without affect-
ing the risk of thromboembolic events (p = 0.20). 
Impact of dosage and timing of initiation and ces-
sation of LMWH/OAC on endpoints are presented 
in Figures 2–5.
Higher dosage of LMWH before SVP was an 
independent risk factor for bleeding and transfu-
sion, with > 60 mg/day as a predictor for these 
events (Figs. 2, 3).
Receiving the first dose of LMWH on the day 
of SVP was an independent predictor of bleeding, 
transfusion and reoperation due to bleeding with 
> 40 mg/day as a predictor for these events (Figs. 2, 4).
Administration of LMWH within 24 h before 
SVP increased the risk of transfusion. Similarly, 
cessation of OAC within fewer than 7 days before 
SVP, increased the risk of transfusion and reop-
eration (Fig. 5). In line with these results, higher 
INR before SVP increased the risk of bleeding 
and transfusion (Suppl. Table 2). Time of LMWH 
initiation after SVP was significantly associated 
with the risk of bleeding (OR 2.110; 95% CI 
1.359–3.287; p = 0.001) and blood transfusion (OR 
2.504; 95% CI 1.546–4.055; p < 0.001). Similarly, 
time of OAC initiation after SVP was associated 
with risk of blood transfusion (OR 1.805; 95% CI 
1.298–2.510; p < 0.001).
Various procedural parameters were also found 
to be relevant study endpoints. 
Each additional minute on CPB significantly 
increased the risk of bleeding (OR 1.017; 95% CI 
1.003–1.032; p = 0.02) and transfusion (OR 1.021; 
95% CI 1.004–1.038; p = 0.014). Furthermore, 
a correlation was found between higher dose of 
protamine at the end of SVP and blood transfusion 
early after surgery (OR 1.002; 95% CI 1.0–1.004; 
Table 1. Baseline clinical characteristics of study 
population (n = 388).
Age [year] 
≥ 65 years
20–85 (63.6 ± 12.57)
224 (57.73%)
Female sex 160 (41.23%)
NYHA class:
   I
   II
   III
   IV
34 (8.76%)
113 (29.13%)
225 (57.99%)
16 (4.12%)
Coronary artery disease* 177 (45.62%)
Previous MI 80 (20.62%)
Previous coronary  
intervention:
    PCI ≤ 6 months pre-TAVI
    CABG 
95 (24.48%)
28 (7.22%)
9 (2.32%)
COPD 25 (6.44%)
Atrial fibrillation 110 (28.35%)
Diabetes mellitus 71 (18.30%)
Hypertension 293 (75.51%)
Renal failure** 27 (6.96%)
Liver failure 19 (4.90%)
History of bleeding 48 (12.37%)
Heart failure*** 253 (65.21%)
Previous stroke/TIA 25 (6.44%)
Laboratory parameters  
before procedure:
    Hemoglobin [g/dL]
    Platelet count [/µL]
    INR
    APTT
    GFR [mL/min/1.73 m2]
    Creatinine [mg/dL]
7.4–19 (13.78 ± 1.68)
114–572 (206 ± 68)
0.83–1.8 (1.03 ± 0.14)
20.8–77.7 (31.06 ± 6.16)
22.78–76.6 (49.54 ± 21.9)
0.52–2.35 (1.15 ± 2.75)
Type of the procedure:
    Multi-SVP
    AVR
    SVR + ascending aorta 
    replacement
    SVP + CABG
    MVpl
    MVR
    TVpl
62 (6.70%)
75 (19.32%)
 
26 (6.7%)
53 (13.65%)
24 (6.18%)
55 (14.17%)
2 (0.5%)
Mechanical prosthesis:
Mitral/Aortic
161 (62.11%)
42 (10.82%)/119 (30.67%)
Biological prosthesis:
Mitral/Aortic
110 (28.35%)
30 (7.73%)/80 (20.61%)
Data are shown as means ± standard deviation or number (per-
centage). *Stenosis > 50%, **GFR < 60 mL/min/1.73 m2 or ≥ 200 
mmol/L, detected in consecutive, in-hospital testing, prior to TAVI, 
or previously diagnosed and treated chronic renal failure; ***Left 
ventricular ejection fraction < 60%. APTT — activated partial throm-
boplastin time; AVR — aortic valve replacement; CABG — coronary 
artery bypass grafting; COPD — chronic obstructive pulmonary dis-
ease; GFR — glomerular filtration rate; INR — international normal-
ized ratio; multi-SVP — multiple valve procedures; MI — myocardial 
infarction; MVpl — mitral valve annuloplasty; MVR — mitral valve 
replacement; NYHA — New York heart Association; PCI — percuta-
neous coronary intervention; SVR + CABG — valve procedures and 
coronary artery bypass graft combined procedure; TAVI — transcath-
eter aortic valve implantation; TIA — transient ischemic attack; TVpl 
— tricuspid valve annuloplasty
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DC
st
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LMWH dosage on the SVP 
nd
LMWH dosage on 2  SVP 
 OR (95% CI) P
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day 40–160 (42.81 ± 9.38) 
LMWH dosage before SVP 
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40–160 (74.64 ± 31.1) 
BA
LMWH dosage on the SVP 
st
LMWH dosage on 1  SVP
1.026 (1.005–1.048) 0.013 
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0.996 (0.985–1.007) 0.48
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LMWH dosage before SVP 
st
LMWH dosage on 1  SVP 
1.201 (1.123–1.282) < 0.001
day 40–160 (42.81 ± 9.38)  
LMWH dosage before SVP 
1.014 (0.989–1.040) 0.25
40–160 (74.64 ± 31.1) 
0.987 (0.950–1.023) 0.47
day 40–80 (54.87 ± 20.84) 
nd
LMWH dosage on 2  SVP
 OR (95% CI) P
LMWH dosage on the SVP 
0.986 (0.962–1.036) 0.52
day 40–160 (66.57 ± 31.21) 
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40–160 (74.64 ± 31.1) 
LMWH dosage before SVP 
 OR (95% CI) P
LMWH dosage on the SVP 
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st
LMWH dosage on 1  SVP
1.024 (0.986–1.062) 0.20
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nd
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OR (95% Cl)
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Figure 2. Impact of dosage of low molecular weight heparin (LMWH) and oral anticoagulation before and after surgical 
valve procedures on study endpoints in multivariate logistic regression analysis; A. Bleeding (n = 153); B. Transfusions 
(n = 203); C. Reoperation (n = 25); D. Thromboembolic events (n = 7). As only 7 thromboembolic events occured, the 
first OR in panel D for LMWH dosage before surgical valve procedures is only displayed in numbers to avoid modify 
the scale x axis; CI — confidence interval; OR — odds ratio.
Figure 1. Impact of periprocedural antithrombotic/antiplatelet therapy on study endpoints in multivariate logistic regres-
sion analysis; A. Bleeding (n = 153); B. Transfusions (n = 203); C. Reoperation (n = 25); D. Thromboembolicevents 
(n = 7); *Combined therapy before SVP: dual antiplatelet therapy 15 (3.8%) patients, triple antithrombotic therapy 
7 (1.8%) patients, LMWH/OAC/NOAC + ASA/clopidogrel 33 (8.5%) patients; **Combined therapy after SVP: dual 
antiplatelet therapy 14 (3.6%) patients, triple antithrombotic therapy 4 (1.0%) patients, LMWH/OAC/NOAC + ASA/
clopidogrel 54 (13.9%) patients as only 7 thromboembotic events occur, we were able to produce only 4 OR in panel 
D; ASA — acetylsalicylic acid; CI — confidence interval; LMWH — low molecular weight heparin; NOAC — non-vitamin 
K antagonists oral anticoagulant; OAC — oral anticoagulation; OR — odds ratio; SVP — surgical valve procedures.
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Figure 3. Impact of low molecular weight heparin (LMWH) dosage administered before surgical valve procedures on 
the study endpoints; A. Impact of LMWH dosage premedication on bleeding; B. Impact of LMWH dosage premedica-
tion on transfusion.
Figure 4. Impact of low molecular weight heparin (LMWH) and oral anticoagulation (OAC) time of cessation before 
surgical valve procedures on transfusion; A. Impact of LMWH cessation before SVP on transfusion; B. Impact the day 
of OAC cessation before SVP on transfusion
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p = 0.04). Activated clotting time after UFH admin-
istration associated with bleeding (OR 0.997; 95% CI 
0.995–0.999; p = 0.004) and thromboembolic events 
(OR 1.006; 95% CI 1.0–1.011; p = 0.048).
Discussion
The primary purpose of early prophylaxis af-
ter SVP is the prevention of valve thrombosis and 
thromboembolic events, which may be a result of 
temporal immobility of post-procedure patients 
[2, 8, 15–19]. Many experimental studies have 
suggested a postprocedural hypercoagulable state 
due to enhanced activation of plasma coagulation 
factors and platelets by surgically injured native 
heart tissue, turbulent flow across the prosthesis, 
and thrombogenicity of prosthesis artificial materi-
als [1]. The necessity of chronic OAC prophylaxis 
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after SVP is well accepted. Chronic OAC provides 
a 75% reduction in the incidence of early throm-
boembolic events [1, 8, 15–19]. However, optimal 
prophylaxis directly after SVP remains unclear, 
especially when considering serious bleeding 
complications are among the most frequently noted 
in-hospital complications [1, 2, 9–12]. 
In this study, serious bleeding affected 13% of 
patients within 72 h after SVP, whereas early valve 
thrombosis was not observed. The only embolic 
events were strokes noted in fewer than 2% of 
subjects. These results are consistent with other 
studies that report bleeding occurs at least twice as 
often as the thromboembolic events in first 3 days 
after SVP, and bleeding is also the main reason for 
early reoperation [1, 2, 9–11, 22–24]. 
A variety of periprocedural antithrombic 
prophylaxis protocols have been proposed [1, 
2, 8–11, 15–19]. Currently, the most common 
antithrombotic prophylaxis regimens are: early 
postoperative bridging with LMWH or UFH started 
on the day of SVP with OAC on the first post-
procedural day or early OAC monotherapy with no 
bridging treatment [1, 2, 9, 25–29]. There is insuf-
ficient evidence to support the use of one of these 
strategies early after SVP [1, 2, 9–11]. Therefore, 
current recommendations regarding antithrom-
botic prophylaxis early after SVP are divergent, 
and a lack of consensus remains [8, 15–19].
Of note, SVP with CPB is responsible for 
significant consumption coagulopathy [1, 13]. Al-
though these hemostasis disturbances are gradu-
ally restored within subsequent days, they trans-
late into high risk of bleeding early after SVP. 
Considering the hemostatic disorders related to 
the procedure and disproportionate risk of bleeding 
compared to valve thrombosis, current prophylactic 
strategies with therapeutic doses of anticoagulants 
may be overly aggressive [1, 11]. 
Surprisingly, despite the absence of strong 
evidence, ESC guidelines recommend UFH bridg-
ing with early OAC implementation, and describe 
LMWH early after SVP as off-label prophylaxis 
[16]. Notably, this recommendation is based 
mainly on empiric, single center data [16, 29]. On 
the other hand, other guidelines and a substantial 
number of current reports suggest that LMWH 
after SVP is as effective as UFH and has a bet-
ter safety profile than UFH, providing a rapidly 
achieved antithrombotic effect and predictable 
action without the necessity of routine laboratory 
monitoring [1, 9–11]. These advantages of LMWH 
translate into a shorter hospital stay and lower 
cost of hospitalization [1, 9–11]. 
Figure 5. Impact of low molecular weight heparin 
(LMWH) dosage administered within 24 h after surgical 
valve procedures on the study endpoints; A. Impact 
of LMWH dosage on SVP day on bleeding; B. Impact 
of LMWH dosage on SVP on transfusion; C. Impact of 
LMWH dosage on SVP day on reoperation.
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The present study confirmed feasibility of 
LMWH early after SVP and described the most 
favorable dosage and timing of LMWH adminis-
tration for optimal periprocedural prophylaxis. It 
was found that the most advantageous dosage of 
LMWH after SVP was 40–60 mg/day, which is equal 
to doses recommended for deep vein thrombosis 
prophylaxis after major surgery and for prolonged 
immobilization of high-risk patients [30]. Several 
other studies have also suggested the beneficial 
safety profile of prophylactic doses of heparins in 
comparison to therapeutic ones early after SVP, 
showing up to a fivefold reduction of major bleeding 
and a similar thromboembolic risk [1, 11]. 
Another insufficiently investigated concern is 
the safest time points for cessation and initiation 
of periprocedural antithrombotic prophylaxis with 
regard to SVP. The present results suggest that 
OAC should be stopped at least 6 days before SVP, 
while LMWH should be stopped 24 h preprocedure. 
These results are to some extent in agreement 
with guidelines that recommend stopping OAC 
5 days before and LMWH between 12 and 24 h 
before major surgical procedures [8, 15–18].
Since this study found that dosage of LMWH 
on the day of SVP affected the safety outcomes, 
herein suggested, is the need for reassessment and 
special caution when considering LMWH initiation 
within the first 24 h of SVP. Furthermore, this espe-
cially deserves more attention given that consensus 
guidelines recommend considering longer delays 
in starting LMWH even up to 48–72 h after high 
bleeding risk procedures such as SVP [8, 15, 16, 18].
It is believed that the results of this study 
make several key contributions to the literature. 
Firstly, the present outcomes highlight the hemo-
static profile of the SVP population in the first 72 h 
post-procedure, suggesting that in this period, 
hemostasis risk is tilted more toward bleeding than 
valve thrombosis. Secondly, in line with concern 
for increased bleeding risk, it is shown herein, that 
if a LMWH strategy is utilized, the most suitable 
approach is to use the reduced dose of LMWH 
as is recommended for prophylaxis of deep vein 
thrombosis equally before and after surgery. Simi-
larly, as in previous studies, the present results 
highlight the presence of risk factors, which can 
modulate the safety and efficacy of antithrombotic 
prophylaxis. It is shown that a higher number of 
implanted prostheses; combined procedures, age, 
female sex, and New York Heart Association class 
of heart failure had meaningful impact on clinical 
endpoints. CPB time, higher value of ACT directly 
after UFH administration, and protamine dose with 
safety endpoints. 
Limitations of the study
This study has several limitations. Firstly, the 
analysis may have limited power considering the 
small sample size; therefore, results should be in-
terpreted cautiously. Secondly, the study population 
was heterogeneous, since it included mechanical 
and biological prosthesis implantation, valvulo-
plasty, as well as procedures combined with CABG. 
Additionally, the rate of bleeding was higher than 
expected. Although only 13% of incidents were 
life-threatening or severe, the rate of bleeding de-
scribed in this study is substantially higher than has 
been previously reported [1, 2, 9–11]. This might 
be explained by the high surgical risk of the study 
population and high rate of complex procedures 
— 29.9% of multi-VP, 25.7% of VP+CABG, 6.7% 
of Bentall procedure or replacement of ascending 
aorta as part of a combined surgery. This might also 
be due to the lack of a unified definition for bleeding 
and thromboembolic events related to SVP. While 
guidelines for reporting complications during long-
term follow-up after SVP exist [20], these recom-
mendations do not address early complications dur-
ing index hospitalization, such as early prosthesis 
thrombus, pericardial effusion, cardiac tamponade 
or excessive post-procedural drainage. Thus, it was 
elected to define early bleeding as per the most 
recent unified definition of perioperative bleeding 
from the International Initiative for Hemostasis 
Management in Cardiac Surgery [21]. Finally, there 
was an inability  to thoroughly assess the impact of 
time of LMWH and OAC initiation after SVP. the 
present results are inconclusive in this regard, since 
time of LMWH/OAC initiation after SVP was biased 
by procedure related events. Although, according 
to the protocol, the first dose of LMWH was to be 
administered 8–12 h after SVP or after hemostasis 
achievement, no patient who experienced bleeding 
during SVP had LMWH started within 48 h. Since 
early post-procedural prophylaxis was withheld 
in cases of procedure related bleeding, it was dif-
ficult to determine optimal time for LMWH/OAC 
initiation after SVP from this data. Future studies 
should seek to address these limitations in a larger, 
carefully selected patient population.
Conclusions
Bleeding complications are the major early 
clinical adverse events after surgical valve pro-
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cedures. Safety and efficacy of LMWH periproce-
dural prophylaxis depends on dosage and time of 
its administration. The most optimal strategy for 
periprocedural antithrombotic prophylaxis in the 
SVP population appears to be LMWH at a dosage 
of 40–60 mg/day, in line with what is recommended 
for deep vein thrombosis prophylaxis, stopped at 
least one day prior to the procedure.
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